131 related articles for article (PubMed ID: 36395704)
1. Early Application of Next-Generation Sequencing Identifies Pancreatic Mass as Metastasis From an EGFR-Mutated Lung Adenocarcinoma.
Chen L; Davelaar J; Gaddam S; Kosari K; Nissen N; Chaux G; Lee C; Vail E; Hendifar A; Gong J; Reckamp K; Osipov A
J Natl Compr Canc Netw; 2022 Nov; 21(1):6-11. PubMed ID: 36395704
[TBL] [Abstract][Full Text] [Related]
2. Comparison of targeted next-generation sequencing with conventional sequencing for predicting the responsiveness to epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) therapy in never-smokers with lung adenocarcinoma.
Han JY; Kim SH; Lee YS; Lee SY; Hwang JA; Kim JY; Yoon SJ; Lee GK
Lung Cancer; 2014 Aug; 85(2):161-7. PubMed ID: 24857785
[TBL] [Abstract][Full Text] [Related]
3. Next-generation sequencing assisted diagnosis of cervical metastasis in EGFR-mutated lung adenocarcinoma: A case report.
Xu L; Li K; Chen X; Chen B; Li J; Wu L
Thorac Cancer; 2021 Oct; 12(19):2622-2627. PubMed ID: 34505336
[TBL] [Abstract][Full Text] [Related]
4. Sequential small cell transformation and T790M mutation in an epidermal growth factor-mutant lung adenocarcinoma: A rare occurrence with significant management implications.
Shastri M; Gupta P; Gupta N; Singh N; Bal A; Srinivasan R; Khosla D
Cytopathology; 2022 Nov; 33(6):732-737. PubMed ID: 35867808
[TBL] [Abstract][Full Text] [Related]
5. EGFR Mutated Lung Adenocarcinoma Metastasis to the Pancreas Mimicking Primary Pancreatic Ductal Carcinoma.
Cao C; Kong MX; Kapali M; Moezardalan K; Shi Q; Azarm A; Lai J
Anticancer Res; 2020 Aug; 40(8):4401-4404. PubMed ID: 32727769
[TBL] [Abstract][Full Text] [Related]
6. Morphological and genetic heterogeneity in multifocal lung adenocarcinoma: The case of a never-smoker woman.
Bonanno L; Calabrese F; Nardo G; Calistri D; Tebaldi M; Tedaldi G; Polo V; Vuljan S; Favaretto A; Conte P; Amadori A; Rea F; Indraccolo S
Lung Cancer; 2016 Jun; 96():52-5. PubMed ID: 27133750
[TBL] [Abstract][Full Text] [Related]
7. Case report: Target and immunotherapy of a lung adenocarcinoma with enteric differentiation,
Yang M; Yu P; He Z; Deng J
Front Immunol; 2023; 14():1266304. PubMed ID: 38332908
[TBL] [Abstract][Full Text] [Related]
8. Utility of incorporating next-generation sequencing (NGS) in an Asian non-small cell lung cancer (NSCLC) population: Incremental yield of actionable alterations and cost-effectiveness analysis.
Tan AC; Lai GGY; Tan GS; Poon SY; Doble B; Lim TH; Aung ZW; Takano A; Tan WL; Ang MK; Tan BS; Devanand A; Too CW; Gogna A; Ong BH; Koh TPT; Kanesvaran R; Ng QS; Jain A; Rajasekaran T; Lim AST; Lim WT; Toh CK; Tan EH; Lim TKH; Tan DSW
Lung Cancer; 2020 Jan; 139():207-215. PubMed ID: 31835042
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of 3rd generation TKI in patients with EGFR mutation lung adenocarcinoma with bone metastases: A review of 3 case reports and literature.
Guo Q; Feng W; Hu S; Ye J; Wang S; Su L; Zhang Y; Zhang D; Zhang W; Xu J; Wei Y
Medicine (Baltimore); 2023 Aug; 102(34):e34545. PubMed ID: 37653755
[TBL] [Abstract][Full Text] [Related]
10. Epidermal growth factor receptor mutation status in pulmonary adenocarcinoma: Multi-institutional data discussion at national conference of "Lung Cancer Management in Indian context".
Nakra T; Mehta A; Bal A; Nambirajan A; Mishra D; Midha D; Gupta N; Arora N; Gupta P; Gupta P; Singh V; Jain D
Curr Probl Cancer; 2020 Jun; 44(3):100561. PubMed ID: 32169258
[TBL] [Abstract][Full Text] [Related]
11. A multicenter blinded study evaluating EGFR and KRAS mutation testing methods in the clinical non-small cell lung cancer setting--IFCT/ERMETIC2 Project Part 1: Comparison of testing methods in 20 French molecular genetic National Cancer Institute platforms.
Beau-Faller M; Blons H; Domerg C; Gajda D; Richard N; Escande F; Solassol J; Denis MG; Cayre A; Nanni-Metellus I; Olschwang S; Lizard S; Piard F; Pretet JL; de Fraipont F; Bièche I; de Cremoux P; Rouquette I; Bringuier PP; Mosser J; Legrain M; Voegeli AC; Saulnier P; Morin F; Pignon JP; Zalcman G; Cadranel J
J Mol Diagn; 2014 Jan; 16(1):45-55. PubMed ID: 24183959
[TBL] [Abstract][Full Text] [Related]
12. Outcome of EGFR-mutated adenocarcinoma NSCLC patients with changed phenotype to squamous cell carcinoma after tyrosine kinase inhibitors: A pooled analysis with an additional case.
Roca E; Pozzari M; Vermi W; Tovazzi V; Baggi A; Amoroso V; Nonnis D; Intagliata S; Berruti A
Lung Cancer; 2019 Jan; 127():12-18. PubMed ID: 30642539
[TBL] [Abstract][Full Text] [Related]
13. Ovarian metastasis from lung adenocarcinoma with ALK-positive rearrangement detected by next generation sequencing: A case report and literatures review.
Jing X; Li F; Meng X; Liu Z; Yu J; Liu B
Cancer Biol Ther; 2017 May; 18(5):279-284. PubMed ID: 28362192
[TBL] [Abstract][Full Text] [Related]
14. Detection of EGFR-Activating and T790M Mutations Using Liquid Biopsy in Patients With EGFR-Mutated Non-Small-Cell Lung Cancer Whose Disease Has Progressed During Treatment With First- and Second-Generation Tyrosine Kinase Inhibitors: A Multicenter Real-Life Retrospective Study.
Minari R; Mazzaschi G; Bordi P; Gnetti L; Alberti G; Altimari A; Gruppioni E; Sperandi F; Parisi C; Guaitoli G; Bettelli S; Longo L; Bertolini F; Pagano M; Bonelli C; Tagliavini E; Nicoli D; Ubiali A; Zangrandi A; Trubini S; Proietto M; Fiorentino M; Tiseo M;
Clin Lung Cancer; 2020 Sep; 21(5):e464-e473. PubMed ID: 32276870
[TBL] [Abstract][Full Text] [Related]
15. Prevalence, clinical and molecular characteristics of early stage EGFR-mutated lung cancer in a real-life West-European cohort: Implications for adjuvant therapy.
Hondelink LM; Ernst SM; Atmodimedjo P; Cohen D; Wolf JL; Dingemans AC; Dubbink HJ; von der Thüsen JH
Eur J Cancer; 2023 Mar; 181():53-61. PubMed ID: 36638752
[TBL] [Abstract][Full Text] [Related]
16. Genomic alterations and clinical outcomes in patients with lung adenocarcinoma with transformation to small cell lung cancer after treatment with EGFR tyrosine kinase inhibitors: A multicenter retrospective study.
Wang W; Xu C; Chen H; Jia J; Wang L; Feng H; Wang H; Song Z; Yang N; Zhang Y
Lung Cancer; 2021 May; 155():20-27. PubMed ID: 33714778
[TBL] [Abstract][Full Text] [Related]
17. Gene alternation of cerebrospinal fluid in patients with leptomeningeal metastases of lung adenocarcinoma using next-generation sequencing.
Yang H; Wen L; Pan Y; Shan C; Hong W; Wang H; Zhou C; Cai L; Zhou C
BMC Cancer; 2022 May; 22(1):580. PubMed ID: 35614407
[TBL] [Abstract][Full Text] [Related]
18. FNA smears as a potential source of DNA for targeted next-generation sequencing of lung adenocarcinomas.
Treece AL; Montgomery ND; Patel NM; Civalier CJ; Dodd LG; Gulley ML; Booker JK; Weck KE
Cancer Cytopathol; 2016 Jun; 124(6):406-14. PubMed ID: 26882436
[TBL] [Abstract][Full Text] [Related]
19. Sequential occurrence of small cell and non-small lung cancer in a male patient: Is it a transformation?
Wahab A; Kesari K; Chaudhary S; Khan M; Khan H; Smith S; Boumber Y
Cancer Biol Ther; 2017 Dec; 18(12):940-943. PubMed ID: 29157085
[TBL] [Abstract][Full Text] [Related]
20. Economic Analysis of Exclusionary EGFR Test Versus Up-Front NGS for Lung Adenocarcinoma in High EGFR Mutation Prevalence Areas.
Yang SC; Yeh YC; Chen YL; Chiu CH
J Natl Compr Canc Netw; 2022 Apr; 20(7):774-782.e4. PubMed ID: 35385830
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]